EMPA-KIDNEY

Last edited 11/2022 and last reviewed 09/2023

EMPA-KIDNEY

• was a RCT of 6609 patients with chronic kidney disease who were randomized to the SGLT2 inhibitor empagliflozin or placebo
• effect of treatment on CVD, progression of kidney disease, and the need for hospitalization in patients with chronic kidney disease was investigated
• mean follow-up was 2.0 years
  
  
• treatment with empagliflozin reduced progression (i.e. worsening) of kidney disease or CV death by 28% compared to placebo
• a consistent benefit was observed in those with or without CVD
  
  
• EMPA-KIDNEY showed consistent benefits among 3569 patients (54.0%) without diabetes and, separately, among 2282 patients (34.5%) with an eGFR of less than 30 ml per minute per 1.73 m2
  
  
• the need for hospitalization by any cause was reduced by 14% in the group who received empagliflozin compared to the group who received placebo

EMPA-KIDNEY trial in patients with chronic kidney disease showed that treatment with empagliflozin reduced the progression of kidney disease or CV death and reduced the need for all-cause hospitalization.

• similar benefit for treatment with empagliflozin was seen regardless of CVD status

Reference:

• The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. NEJM; November 4, 2022 DOI: 10.1056/NEJMoa2204233